Moreover, in melanoma cells, melanogenesis can regulate the expression of the transcription factor, hypoxia-inducible factor 1α (HIF-1α), the key molecule for the cancer cell resistance to anti-angiogenic therapies, decreasing the effectiveness of the treatments and the survival rates during stages III and IV of melanoma [4–7]. This evidence concerns the gene HIF1A and cancer.